EU-Projects at the MPIB
Coordinator: Andreas Ladurner, EMBL Heidelberg (LMU, Munich from March 1, 2011 onwards)
Manager: Marzia Sidri, EMBL Heidelberg (Corey Laverty, LMU Munich from March 1, 2011 onwards)
MPI Group: Juerg Müller
16 Partners (21 Labs) in 11 countries, budget: 4,6 Mio Euro.
The main objective of the Network is to provide young researchers with world-class research & training in chromatin biology. Complementary approaches in structural biology, biophysics, cell biology, live-cell imaging, biochemistry, genetics, genomics and bioinformatics will be used in collaborative projects to determine how nucleosomes are remodeled during transcription, when genes are silenced, as cell divide, as stem cells differentiate, during organismal development and in human disease.
(1.2.2011- 31.1.2015)
Coordinator: Albert Heck, Utrecht University
Manager: Reinout Raijmakers, Utrecht University
MPI Group: M.Mann
12 Partners (15 Labs) in 9 countries, budget: 9,8 Mio Euro.
Major objective: to provide state-of-the-art proteomics technologies to the European biological and biomedical research community. The leading proteomic labs forming Prime-XS will provide access to their facilities, develop new technologies, and will disseminate knowledge and expertise through meetings and training events.
Coordinator: L. van den Berg, UMC Utrecht
Manager: P. Berk, UMC Utrecht
MPI Group: M.Mann
15 Partners (16 Labs) in 7 countries, budget: 11,8 Mio Euro.
Major objective is a better understanding and treatment of the neurotropic degenerative disease Amyotrophic Lateral Sclerosis. Euro-MOTOR aims to detect key genetic drivers of disease susceptibility/progression and to generate a model of disease which can be validated in patients to pave the way for novel therapeutic interventions for this disabling and fatal disease.
(1.4.2008-31.3.2013)
Coordinator: M.Mann, MPI Biochemistry
Manager: AK Werenskiold, MPI Biochemistry
MPI Groups: Mann, Hartl, Baumeister
10 Partners (12 Labs) in 7 countries, budget. 11,7 Mio Euro. Major objectives include the development of much more powerful instrumentation and novel proteomics methods. The goal is to annotate quantitatively the human proteome with respect to protein localization and dynamics.
National Coordination: W. Baumeister, MPI Biochemistry
National Manager: J. Rieder, MPI Biochemistry
Preparatory Phase: 12 partners in 5 countries, budget. 4.5 Mio Euro. Major objectives: to set up a framework consisting of distributed centres (during preparatory phase 7 core centres), each of which will maintain a set of core technologies such as protein production, NMR, crystallography and different forms of microscopy, including electron microscopy and combine this with a specific biological focus that will drive the development of technological and methodological expertise, notably for the analysis of functional complexes.
Operational Phase: Currently 20 partners in 8 countries, 8 core centres and 7 associate centres. Major objectives: to provide European researchers from academia and industry with access to state-of-the-art structural biology technologies, scientific expertise and training and, by driving innovation at the boundaries between these technologies, stimulate and facilitate research that integrates an understanding of biological structure with cellular function.
(1.1.2004-30.6.2009)
Coordinator: F-U. Hartl, MPI Biochemistry
Manager: AK Werenskiold, MPI Biochemistry
11 Partners (14 Labs) in 7 countries, budget. 12 Mio Euro. Major objectives include the establishment of a broadly applicable platform of routine methods for the analysis of protein interaction networks.
(1.3.2004-31.08.2009)
Coordinator: A. Engel, Biozentrum, Basel
Scientific Manager: AK Werenskiold MPI Biochemistry
16 Partners (18 Labs) in 7 countries, budget. 10 Mio Euro. Major objectives include the establishment of synergies between different technologies in structural research and of an extensive training programme in all fields related to structural biology
rss
EU FP7 Marie Curie Initial Training Network, Nucleosome4D
Top
Print